Form 4: Celldex Therapeutics SVP Granted Stock Options

Margo Heath-Chiozzi, SVP of Regulatory Affairs at Celldex Therapeutics, was granted incentive stock options to purchase 82,000 shares of common stock.

Summary

• Margo Heath-Chiozzi, the SVP of Regulatory Affairs at Celldex Therapeutics, Inc. [CLDX], was granted incentive stock options on June 13, 2024.
• The options allow her to purchase 82,000 shares of Celldex's common stock at an exercise price of $36.43 per share.
• The options vest 25% on June 13, 2025, and the remaining 75% vest quarterly over the following 12 quarters.
• The options expire on June 13, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for executives.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and company growth.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders. This grant is consistent with industry practices.

Comparison to Industry Standards

• Executive compensation packages, including stock options, are common in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron also use stock options as part of their executive compensation plans.
• The vesting schedule and exercise price are typical for such grants.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the executive's performance leads to company growth.
• It incentivizes the executive to work towards the company's success, which benefits employees and other stakeholders.

Key Dates